Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:IMMP NASDAQ:INCR NASDAQ:PMVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.23-3.9%$2.74$2.15▼$6.59$14.68M1.53109,613 shs6,706 shsIMMPPrima BioMed$0.38-3.1%$0.44$0.29▼$3.53$57.27M2.211.03 million shs581,594 shsINCRInterCure$1.02-2.9%$0.85$0.68▼$1.77$57.42M1.3830,778 shs21,400 shsPMVPPMV Pharmaceuticals$1.12-5.9%$1.32$0.94▼$1.88$63.47M1.36403,189 shs314,642 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+2.44%-6.41%+10.53%+26.79%-27.90%IMMPPrima BioMed-4.52%-12.60%-15.45%-85.92%-78.65%INCRInterCure+0.96%-1.87%+21.67%+28.02%-33.12%PMVPPMV Pharmaceuticals+2.59%0.00%-13.14%-27.44%+27.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.23-3.9%$2.74$2.15▼$6.59$14.68M1.53109,613 shs6,706 shsIMMPPrima BioMed$0.38-3.1%$0.44$0.29▼$3.53$57.27M2.211.03 million shs581,594 shsINCRInterCure$1.02-2.9%$0.85$0.68▼$1.77$57.42M1.3830,778 shs21,400 shsPMVPPMV Pharmaceuticals$1.12-5.9%$1.32$0.94▼$1.88$63.47M1.36403,189 shs314,642 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx+2.44%-6.41%+10.53%+26.79%-27.90%IMMPPrima BioMed-4.52%-12.60%-15.45%-85.92%-78.65%INCRInterCure+0.96%-1.87%+21.67%+28.02%-33.12%PMVPPMV Pharmaceuticals+2.59%0.00%-13.14%-27.44%+27.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 2.00HoldN/AN/AIMMPPrima BioMed 1.75Reduce$5.501,370.59% UpsideINCRInterCure 1.00SellN/AN/APMVPPMV Pharmaceuticals 2.67Moderate Buy$5.00344.44% UpsideCurrent Analyst Ratings BreakdownLatest BLRX, INCR, PMVP, and IMMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026PMVPPMV Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$6.00 ➝ $5.004/29/2026PMVPPMV Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026BLRXBioLineRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026PMVPPMV Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/27/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/13/2026IMMPPrima BioMed Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $1.003/13/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$1.18M12.18N/AN/A$5.36 per share0.61IMMPPrima BioMed$4.08M13.51N/AN/A$0.63 per share0.59INCRInterCure$78.47M0.70N/AN/A$2.11 per share0.48PMVPPMV PharmaceuticalsN/AN/AN/AN/A$1.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$1.17M-$1.92N/AN/AN/A-563.70%-37.73%-19.42%8/13/2026 (Estimated)IMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/AN/AINCRInterCure-$10.37M$0.0333.53N/AN/AN/AN/AN/AN/APMVPPMV Pharmaceuticals-$77.74M-$1.49N/AN/AN/AN/A-68.98%-62.70%8/6/2026 (Estimated)Latest BLRX, INCR, PMVP, and IMMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026BLRXBioLineRx-$1.04-$0.36+$0.68-$0.36$0.34 million$0.48 million5/12/2026Q1 2026PMVPPMV Pharmaceuticals-$0.41-$0.34+$0.07-$0.34N/AN/A4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 million3/24/2026Q4 2025BLRXBioLineRx-$0.50-$0.34+$0.16N/A$0.49 million$0.19 million3/6/2026Q4 2025PMVPPMV Pharmaceuticals-$0.40-$0.34+$0.06-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.161.581.43IMMPPrima BioMedN/A2.97N/AINCRInterCure0.201.480.97PMVPPMV PharmaceuticalsN/A11.1411.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%IMMPPrima BioMed2.32%INCRInterCure8.34%PMVPPMV Pharmaceuticals90.20%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%IMMPPrima BioMed3.07%INCRInterCure0.24%PMVPPMV Pharmaceuticals7.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.37 million4.32 millionOptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionableINCRInterCure35054.68 million54.55 millionOptionablePMVPPMV Pharmaceuticals5053.33 million49.30 millionOptionableBLRX, INCR, PMVP, and IMMP HeadlinesRecent News About These CompaniesWhy PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial ActivityJune 3 at 9:31 PM | finance.yahoo.comWhy PMV Pharmaceuticals, Inc. (PMVP) Faces Funding Concerns Despite Positive Trial ActivityJune 2 at 10:11 AM | insidermonkey.comPMV Pharmaceuticals (PMVP) price target decreased by 37.50% to 4.84April 28, 2026 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | finanznachrichten.dePMV Pharmaceuticals Announces Board Chair TransitionApril 22, 2026 | globenewswire.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Invest In Growth?April 20, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.84%March 9, 2026 | aaii.comAPMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsMarch 6, 2026 | globenewswire.comNew England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid TumorsFebruary 27, 2026 | finance.yahoo.comWhy PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 8.04%February 27, 2026 | aaii.comAPMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial ComparisonNovember 23, 2025 | defenseworld.netDPMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)November 12, 2025 | msn.comPMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate HighlightsNovember 12, 2025 | markets.businessinsider.comIs PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?October 28, 2025 | finance.yahoo.comPMV Pharmaceuticals stock rises on positive cancer drug trial dataOctober 24, 2025 | in.investing.comPMV Pharmaceuticals announces updated rezatapopt monotherapy interim dataOctober 24, 2025 | msn.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a ...October 24, 2025 | finanznachrichten.dePMV Pharma Presents Promising Phase 2 Trial Results for Rezatapopt at 2025 AACR-NCI-EORTC ConferenceOctober 24, 2025 | quiverquant.comQPMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationOctober 24, 2025 | globenewswire.comPMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular ...October 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesFrom High-Yield to High-Growth: 3 Stocks Boosting DividendsBy Leo Miller | May 18, 20263 Crucial Aerospace Component Makers That Analysts LoveBy Nathan Reiff | May 16, 2026AI Dividend Increases: 3 Massive Winners Boosting PayoutsBy Leo Miller | May 11, 2026The Stars Are Aligning For Apple: Get Ready for $300By Sam Quirke | May 11, 20263 Dividend Kings That Earn Their Crown Every QuarterBy Chris Markoch | May 31, 2026BLRX, INCR, PMVP, and IMMP Company DescriptionsBioLineRx NASDAQ:BLRX$3.23 -0.13 (-3.87%) Closing price 04:00 PM EasternExtended Trading$3.24 +0.02 (+0.46%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Prima BioMed NASDAQ:IMMP$0.38 -0.01 (-3.09%) Closing price 04:00 PM EasternExtended Trading$0.38 +0.00 (+0.11%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.InterCure NASDAQ:INCR$1.02 -0.03 (-2.86%) Closing price 03:59 PM EasternExtended Trading$1.01 -0.01 (-1.27%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.PMV Pharmaceuticals NASDAQ:PMVP$1.12 -0.07 (-5.88%) Closing price 04:00 PM EasternExtended Trading$1.12 0.00 (0.00%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
